Minkyu R. Jung

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.

Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 27, 2026

In Situ Confinement of 0D Halometallates Within Deep Eutectic Solvents: From Systematic Screening to Metal-Tunable Luminescence for Anti-Counterfeiting Eutectogels.

In Situ Confinement of 0D Halometallates Within Deep Eutectic Solvents: From Systematic Screening to Metal-Tunable Luminescence for Anti-Counterfeiting Eutectogels.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: April 14, 2026

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Journal: The New England journal of medicine

Published: March 25, 2026

Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.

Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA-altered metastatic or recurrent gastric cancer.

Journal: The oncologist

Published: March 03, 2026

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.

Treatment patterns and clinical outcomes of metastatic gastric cancer in South Korea: real-world evidence from retrospective electronic medical records data.

Journal: BMC cancer

Published: December 26, 2025

A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.

A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.

Journal: Cancer research and treatment

Published: December 10, 2025

Korean Practical Guidelines for Geriatric Assessment and Management of Older Adults with Cancer: A Korean Cancer Association Guideline for Geriatric Oncology.

Korean Practical Guidelines for Geriatric Assessment and Management of Older Adults with Cancer: A Korean Cancer Association Guideline for Geriatric Oncology.

Journal: Cancer research and treatment

Published: November 22, 2025

Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum.

Real-World Outcomes and Biomarker Analysis Based on Routine Clinical, Laboratory, and Pathologic Parameters in Metastatic or Unresectable Esophageal Cancer Treated with First-Line Anti-PD-1 Plus Fluoropyrimidine and Platinum.

Journal: Cancers

Published: August 07, 2025

Impact of Junior Physicians' Resignation on Palliative Sedation Practices: A Retrospective Single-Center Study in South Korea.

Impact of Junior Physicians' Resignation on Palliative Sedation Practices: A Retrospective Single-Center Study in South Korea.

Journal: Journal of hospice and palliative care

Published: July 16, 2025

Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).

Bevacizumab plus Erlotinib in Advanced Solid Cancers with Krebs Cycle Gene Mutations: A Multicenter Phase II Study (BRISK; KCSG AL22-16).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 09, 2025

Development of 3D Reversible Smart Energy-Saving Devices for Adaptive Energy Management.

Development of 3D Reversible Smart Energy-Saving Devices for Adaptive Energy Management.

Journal: Advanced materials (Deerfield Beach, Fla.)

Published: April 23, 2025

Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 13, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026